◎ Sugi Atlas

Atlas / Drug / Temsirolimus

Temsirolimus

drug
On this page

Also known as CCI-779ToriselSID520036SID144206068

Summary

Temsirolimus (CHEMBL1201182) is an approved small molecule (ATC L01EG01) targeting MTOR; indicated across 88 conditions including renal cell carcinoma and neoplasm; with CIViC clinical evidence for 15 variant-indication associations (e.g. KRAS Mutation in endometrial cancer).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: L01EG01
  • Targets: 1 (MTOR)
  • Indications: 88 conditions
  • Clinical trials: 197
  • Precision-oncology evidence (CIViC): 15 variant–indication associations
  • Chemistry: 1030.3 Da · C56H87NO16

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1201182
NameTemsirolimus
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID6918289
ATCL01EG01
Molecular formulaC56H87NO16
Molecular weight1030.3
InChIKeyCBPNZQVSJQDFBE-FUXHJELOSA-N

SMILES: C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OC(=O)C(C)(CO)CO)C)/C)O)OC)C)C)/C)OC

IUPAC name: [(1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl] 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate

Also known as: CCI-779, Temsirolimus, Torisel, TEMSIROLIMUS, temsirolimus, SID520036, SID144206068

Patent coverage: 8,502 distinct patent families (25,195 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
MTORmechanistic target of rapamycin kinaseInhibition5.898.3% (common-essential)P42345

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: ATP-binding cassette sub-family C member 4, Serine/threonine-protein kinase mTOR, Synaptic vesicular amine transporter, ATP-binding cassette sub-family C member 2, ATP-binding cassette sub-family C member 3, Bile salt export pump.

Bioactivity

ChEMBL activities: 7 potent at pChembl ≥ 5 of 11 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
MTOR5.75IC501760nMCHEMBL_ACT_25044903
MTOR5.75IC501760nMCHEMBL_ACT_25872953
MTOR5.75IC501760nMCHEMBL_ACT_29205857
MTOR5.75IC501760nMCHEMBL_ACT_6188454
MTOR5.64IC502290nMCHEMBL_ACT_23207010
ABCB115.57IC502690nMCHEMBL_ACT_18129036
ABCB115.54AC502900nMCHEMBL_ACT_25126989

Target pathways

Aggregated over 1 target gene(s): MTOR.

Top Reactome pathways

41 total, by targets touching each:

PathwayTargetsGenes
PIP3 activates AKT signaling1MTOR
Adaptive Immune System1MTOR
Signal Transduction1MTOR
Macroautophagy1MTOR
Disease1MTOR
MTOR signalling1MTOR
mTORC1-mediated signalling1MTOR
Immune System1MTOR
Signaling by VEGF1MTOR
Generic Transcription Pathway1MTOR
PI3K/AKT Signaling in Cancer1MTOR
Cellular responses to stress1MTOR
Cellular response to heat stress1MTOR
HSF1-dependent transactivation1MTOR
Transcriptional Regulation by TP531MTOR
Energy dependent regulation of mTOR by LKB1-AMPK1MTOR
Regulation of T cell activation by CD28 family1MTOR
Co-stimulation by CD281MTOR
CD28 dependent PI3K/Akt signaling1MTOR
VEGFA-VEGFR2 Pathway1MTOR
VEGFR2 mediated vascular permeability1MTOR
TP53 Regulates Metabolic Genes1MTOR
Regulation of TP53 Activity1MTOR
Diseases of signal transduction by growth factor receptors and second messengers1MTOR
Constitutive Signaling by AKT1 E17K in Cancer1MTOR
Regulation of TP53 Degradation1MTOR
Regulation of TP53 Expression and Degradation1MTOR
PTEN Regulation1MTOR
RNA Polymerase II Transcription1MTOR
Gene expression (Transcription)1MTOR

Dominant GO biological processes

GO termTargets
regulation of cell growth1
T-helper 1 cell lineage commitment1
heart morphogenesis1
heart valve morphogenesis1
energy reserve metabolic process1
‘de novo’ pyrimidine nucleobase biosynthetic process1
inflammatory response1
DNA damage response1
cytoskeleton organization1
germ cell development1
regulation of cell size1
cellular response to starvation1
response to heat1
response to virus1
post-embryonic development1

Indications & clinical

Indications

88 indications (5 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
renal cell carcinoma4MONDO:0005086EFO:0000681
neoplasm4MONDO:0005070EFO:0000616
mantle cell lymphoma4MONDO:0018876EFO:1001469
clear cell renal carcinoma4MONDO:0005005EFO:0000349
lymphoma3MONDO:0005062EFO:0000574
alveolar rhabdomyosarcoma3MONDO:0009994EFO:0000248
breast carcinoma3MONDO:0004989EFO:0000305
embryonal rhabdomyosarcoma3MONDO:0009993EFO:0000437
breast neoplasm3MONDO:0021100EFO:0003869
hepatoblastoma3MONDO:0018666EFO:1000292
myelodysplastic syndrome2MONDO:0018881EFO:0000198
rheumatoid arthritis2MONDO:0008383EFO:0000685
small cell lung carcinoma2MONDO:0008433EFO:0000702
Hodgkins lymphoma2MONDO:0004952EFO:0000183
acute myeloid leukemia2MONDO:0018874EFO:0000222
non-small cell lung carcinoma2MONDO:0005233EFO:0003060
endometrioid adenocarcinoma2MONDO:0005026EFO:0000466
head and neck squamous cell carcinoma2MONDO:0010150EFO:0000181
hepatocellular carcinoma2MONDO:0007256EFO:0000182
non-Hodgkin lymphoma2MONDO:0018908EFO:0005952
plasma cell myeloma2MONDO:0009693EFO:0001378
gliosarcoma2MONDO:0016681EFO:1001465
cutaneous melanoma2MONDO:0005012EFO:0000389
diffuse large B-cell lymphoma2MONDO:0018905EFO:0000403
glioblastoma2MONDO:0018177EFO:0000519
ischemic disease2MONDO:0005053EFO:0000556
leukemia2MONDO:0005059EFO:0000565
neuroblastoma2MONDO:0005072EFO:0000621
osteosarcoma2MONDO:0009807EFO:0000637
sarcoma2MONDO:0005089EFO:0000691
squamous cell carcinoma2MONDO:0005096EFO:0000707
melanoma2MONDO:0005105EFO:0000756
relapsing-remitting multiple sclerosis2MONDO:0005314EFO:0003929
endometrial carcinoma2MONDO:0002447EFO:1001512
adenoma2MONDO:0004972EFO:0000232
peripheral arterial disease2MONDO:0005386EFO:0004265
pancreatic endocrine carcinoma2MONDO:0005893EFO:0007416
fallopian tube carcinoma2MONDO:0006206EFO:1000251
somatostatinoma2MONDO:0006976EFO:1001187
ganglioneuroblastoma2MONDO:0005035EFO:0000502
central nervous system neoplasm2MONDO:0006130EFO:1000158
uterine carcinosarcoma2MONDO:0006485EFO:1000613
soft tissue sarcoma2MONDO:0018078EFO:1001968
fallopian tube neoplasm2MONDO:0021092MONDO:0002158
kidney cancer2MONDO:0002367MONDO:0002367
ovarian cancer2MONDO:0008170MONDO:0008170
endometrium neoplasm2MONDO:0021251MONDO:0011962
pancreatic insulinoma2MONDO:0024677MONDO:0024677
uterine corpus cancer2MONDO:0006003EFO:0007532
pancreatic insulin-producing neuroendocrine tumor2MONDO:0005048EFO:0000549
exocrine pancreatic carcinoma2MONDO:0005192EFO:0002618
rhabdomyosarcoma2MONDO:0005212EFO:0002918
carcinoid tumor2MONDO:0005369MONDO:0024503
brain neoplasm1MONDO:0021211EFO:0003833
male breast carcinoma1MONDO:0005628EFO:0006861
adenocarcinoma1MONDO:0004970EFO:0000228
carcinoma1MONDO:0004993EFO:0000313
chronic myeloid leukemia1MONDO:0011996EFO:0000339
colorectal adenocarcinoma1MONDO:0005008EFO:0000365
prostate adenocarcinoma1MONDO:0005082EFO:0000673
anaplastic astrocytoma1MONDO:0016684EFO:0002499
anaplastic oligodendroglioma1MONDO:0016696EFO:0002501
female reproductive organ cancer1MONDO:0001416EFO:1001331
diffuse intrinsic pontine glioma1MONDO:0006033EFO:1000026
peritoneal neoplasm1MONDO:0006901MONDO:0002087
glioma1MONDO:0021042MONDO:0003268
lung neoplasm1MONDO:0021117MONDO:0008903
astrocytoma (excluding glioblastoma)1MONDO:0019781MONDO:0016691
prostate carcinoma1MONDO:0005159EFO:0001663
colonic neoplasm1MONDO:0005401EFO:0004288
oligodendroglioma1MONDO:0016695MONDO:0002543
colorectal neoplasm1MONDO:0005335MONDO:0005575
paraganglioma0MONDO:0000448EFO:1000453

15 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 197.

Phase distribution

PhaseTrials
PHASE278
PHASE169
PHASE1/PHASE228
PHASE39
Not specified9
EARLY_PHASE13
PHASE41

Top trials by phase / activity

NCTPhaseStatusTitle
NCT01180049PHASE4COMPLETEDComparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma
NCT00980460PHASE3ACTIVE_NOT_RECRUITINGRisk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer
NCT02567435PHASE3ACTIVE_NOT_RECRUITINGCombination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
NCT04433572PHASE3RECRUITINGTemsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee
NCT00065468PHASE3COMPLETEDStudy Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma
NCT00083993PHASE3TERMINATEDStudy Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer
NCT00117598PHASE3COMPLETEDStudy Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
NCT00474786PHASE3COMPLETEDTemsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib
NCT00631371PHASE3COMPLETEDStudy Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
NCT01646021PHASE3COMPLETEDStudy of Ibrutinib (a Bruton’s Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy
NCT00977574PHASE2ACTIVE_NOT_RECRUITINGPaclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
NCT01396408PHASE2ACTIVE_NOT_RECRUITINGA Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours
NCT01946529PHASE2ACTIVE_NOT_RECRUITINGTherapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors
NCT02693535PHASE2RECRUITINGTAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
NCT03297606PHASE2RECRUITINGCanadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
NCT00012142PHASE2COMPLETEDCCI-779 in Treating Patients With Prostate Cancer
NCT00016328PHASE2COMPLETEDCCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme
NCT00022464PHASE2COMPLETEDCCI-779 in Treating Patients With Metastatic Melanoma
NCT00022724PHASE1/PHASE2COMPLETEDCCI-779 in Treating Patients With Malignant Glioma
NCT00028028PHASE2COMPLETEDCCI-779 in Treating Patients With Extensive-Stage Small Cell Lung Cancer
NCT00033267PHASE2COMPLETEDCCI-779 in Treating Patients With Mantle Cell Non-Hodgkin’s Lymphoma
NCT00062751PHASE2COMPLETEDStudy Evaluating Temsirolimus (CCI-779) In Breast Neoplasms
NCT00071968PHASE2COMPLETEDNeoadjuvant CCI-779 Followed By Radical Prostatectomy in Treating Patients With Newly Diagnosed Prostate Cancer Who Have a High Risk of Relapse
NCT00072176PHASE2COMPLETEDTemsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer
NCT00075647PHASE2COMPLETEDCCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
NCT00076206PHASE2TERMINATEDStudy Evaluating CCI-779 in Active Rheumatoid Arthritis on Concomitant Methotrexate Therapy
NCT00079235PHASE2COMPLETEDCCI-779 in Treating Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small Cell Lung Cancer
NCT00079456PHASE2COMPLETEDTemsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT00084916PHASE2COMPLETEDCCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase
NCT00086840PHASE2TERMINATEDCCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT00087074PHASE2COMPLETEDCCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor
NCT00093782PHASE2COMPLETEDTemsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma
NCT00106353PHASE1/PHASE2COMPLETEDStudy Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors
NCT00109967PHASE2COMPLETEDCCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma
NCT00112736PHASE1/PHASE2COMPLETEDErlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma
NCT00112840PHASE1/PHASE2COMPLETEDCCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer
NCT00228397PHASE2COMPLETEDStudy Evaluating CCI-779 in Relapsing Multiple Sclerosis
NCT00281957PHASE2COMPLETEDSorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery
NCT00290472PHASE2COMPLETEDCCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin’s Lymphoma or Chronic Lymphocytic Leukemia
NCT00329719PHASE1/PHASE2COMPLETEDSorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma

Clinical evidence (CIViC)

Variant × indication × effect (15 predictive associations from 16 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
KRAS MutationEndometrial CancerSensitivity/ResponseRidaforolimus + TemsirolimusCIViC BEID894
PIK3CA MutationEndometrial CancerSensitivity/ResponseTemsirolimus + RidaforolimusCIViC BEID892
PTEN LossEndometrial CancerResistanceTemsirolimus + RidaforolimusCIViC BEID893
KIAA1549::BRAF FusionSpindle Cell SarcomaSensitivity/ResponseSorafenib + Bevacizumab + TemsirolimusCIViC CEID1664 +1
NF2 K159fsBreast CancerSensitivity/ResponseTemsirolimusCIViC CEID715
PTPRD R995CEwing SarcomaSensitivity/ResponseIGF1R Monoclonal Antibody + TemsirolimusCIViC CEID10061
PTPRD T781AEwing SarcomaSensitivity/ResponseTemsirolimus + IGF1R Monoclonal AntibodyCIViC CEID10062
MTOR Q2223KClear Cell Renal Cell CarcinomaSensitivity/ResponseTemsirolimusCIViC DEID4522
PIK3CA E542KThyroid CancerSensitivity/ResponsePerifosine + TemsirolimusCIViC DEID1626
PIK3CA H1047RThyroid CancerSensitivity/ResponsePerifosine + TemsirolimusCIViC DEID1625
PTEN LossEndometrial CancerSensitivity/ResponseTemsirolimusCIViC DEID1614
PTEN LossProstate CancerSensitivity/ResponseTemsirolimusCIViC DEID507
PTEN R130*Thyroid CancerSensitivity/ResponsePerifosine + TemsirolimusCIViC DEID1627
VHL LossRenal CarcinomaSensitivity/ResponseTemsirolimusCIViC DEID1035
VHL Loss-of-functionRenal Cell CarcinomaSensitivity/ResponseTemsirolimusCIViC DEID4828

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

158 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
ALPELISIBChEMBLPhase 4 (approved)MTOR
AMIODARONEChEMBLPhase 4 (approved)MTOR
AMITRIPTYLINEChEMBLPhase 4 (approved)MTOR
AMOXAPINEChEMBLPhase 4 (approved)MTOR
AMSACRINEChEMBLPhase 4 (approved)MTOR
AZACITIDINEChEMBLPhase 4 (approved)MTOR
BROMOCRIPTINEChEMBLPhase 4 (approved)MTOR
CARVEDILOLChEMBLPhase 4 (approved)MTOR
CHLOROQUINEChEMBLPhase 4 (approved)MTOR
CHLORPROMAZINEChEMBLPhase 4 (approved)MTOR
CLEMASTINEChEMBLPhase 4 (approved)MTOR
CLOMIPRAMINEChEMBLPhase 4 (approved)MTOR
COPANLISIBChEMBLPhase 4 (approved)MTOR
CYCLOBENZAPRINEChEMBLPhase 4 (approved)MTOR
CYCLOSPORINEChEMBLPhase 4 (approved)MTOR
CYPROHEPTADINEChEMBLPhase 4 (approved)MTOR
CYTARABINEChEMBLPhase 4 (approved)MTOR
DASATINIBChEMBLPhase 4 (approved)MTOR
DEQUALINIUMChEMBLPhase 4 (approved)MTOR
DESIPRAMINEChEMBLPhase 4 (approved)MTOR
DISULFIRAMChEMBLPhase 4 (approved)MTOR
DOMPERIDONEChEMBLPhase 4 (approved)MTOR
DOPAMINEChEMBLPhase 4 (approved)MTOR
DOXAZOSINChEMBLPhase 4 (approved)MTOR
EBASTINEChEMBLPhase 4 (approved)MTOR
EMETINEChEMBLPhase 4 (approved)MTOR
EPINEPHRINEChEMBLPhase 4 (approved)MTOR
EVEROLIMUSChEMBLPhase 4 (approved)MTOR
FELODIPINEChEMBLPhase 4 (approved)MTOR
FENOFIBRATEChEMBLPhase 4 (approved)MTOR
FLUOROURACILChEMBLPhase 4 (approved)MTOR
FLUOXETINEChEMBLPhase 4 (approved)MTOR
FLUPHENAZINEChEMBLPhase 4 (approved)MTOR
FLUSPIRILENEChEMBLPhase 4 (approved)MTOR
GUANABENZChEMBLPhase 4 (approved)MTOR
HALOPERIDOLChEMBLPhase 4 (approved)MTOR
HYDROQUINONEChEMBLPhase 4 (approved)MTOR
IDARUBICINChEMBLPhase 4 (approved)MTOR
IMIPRAMINEChEMBLPhase 4 (approved)MTOR
INDOMETHACINChEMBLPhase 4 (approved)MTOR
ISOPROTERENOLChEMBLPhase 4 (approved)MTOR
ISOTRETINOINChEMBLPhase 4 (approved)MTOR
LOPERAMIDEChEMBLPhase 4 (approved)MTOR
LORATADINEChEMBLPhase 4 (approved)MTOR
MAPROTILINEChEMBLPhase 4 (approved)MTOR
MASOPROCOLChEMBLPhase 4 (approved)MTOR
MEMANTINEChEMBLPhase 4 (approved)MTOR
METHYLDOPAChEMBLPhase 4 (approved)MTOR
MIBEFRADILChEMBLPhase 4 (approved)MTOR
MIFEPRISTONEChEMBLPhase 4 (approved)MTOR
MITOXANTRONEChEMBLPhase 4 (approved)MTOR
NAFTOPIDILChEMBLPhase 4 (approved)MTOR
NICARDIPINEChEMBLPhase 4 (approved)MTOR
NICLOSAMIDEChEMBLPhase 4 (approved)MTOR
NIFEDIPINEChEMBLPhase 4 (approved)MTOR
NORTRIPTYLINEChEMBLPhase 4 (approved)MTOR
PACLITAXELChEMBLPhase 4 (approved)MTOR
PANCURONIUMChEMBLPhase 4 (approved)MTOR
PAROXETINEChEMBLPhase 4 (approved)MTOR
PENTAMIDINE ISETHIONATEChEMBLPhase 4 (approved)MTOR

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot